Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now
Key takeaways
- Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now Jabran Kundi Fri, July 3, 2026 at 8:41 PM GMT+7 2 min read GPCR Structure Therapeutics Inc.
- In addition to Prakhar Agrawal, BMO Capital analyst Evan Seigerman reiterated a Buy rating on Structure Therapeutics Inc.
- In addition to weight loss, the drug showed benefits such as lowering blood pressure and reducing inflammation without causing a significant increase in heart rate.
Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now Jabran Kundi Fri, July 3, 2026 at 8:41 PM GMT+7 2 min read GPCR Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 8 Hidden Multibagger Stocks to Buy Now. On June 7, Cantor Fitzgerald analyst Prakhar Agrawal reiterated a Buy rating on Structure Therapeutics Inc. (NASDAQ:GPCR) and set a price target of $101. The firm's price target implies an additional 95% upside from current levels.
In addition to Prakhar Agrawal, BMO Capital analyst Evan Seigerman reiterated a Buy rating on Structure Therapeutics Inc. (NASDAQ:GPCR) on June 5 and set a target price of $145. The analyst believes that the company's most advanced weight-loss drug, aleniglipron, showed strong results in clinical trials. The data showed significant and sustained weight loss, along with a favorable safety profile with no major liver concerns. These positive results suggest aleniglipron could become one of the leading oral obesity treatments on the market.
In addition to weight loss, the drug showed benefits such as lowering blood pressure and reducing inflammation without causing a significant increase in heart rate. Evan Seigerman believes these results highlight the drug's broader health benefits. As the demand for obesity treatment grows, aleniglipron has the potential to become an attractive option due to its oral administration and lower-cost alternative to injectables.